4.1 Review

CE-MS-based proteomics in biomarker discovery and clinical application

期刊

PROTEOMICS CLINICAL APPLICATIONS
卷 9, 期 3-4, 页码 322-334

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201400115

关键词

Biomarker; Capillary electrophoresis; Clinical proteomics; Mass spectrometry; Peptidomics

资金

  1. FP7 program Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction (TransBioBC) [FP-HEALTH-INNOVATION-2013-2, GA 601933]
  2. FP7 program Clinical and system-omics for the identification of the Molecular Determinants of established Chronic Kidney Disease (iMODE-CKD) [PEOPLE-ITN-GA-2013-608332]
  3. FP7 program Molecular Medicine for Bladder Cancer [PITN-GA-2012-317450-BCMolMed]
  4. FP7 program Systems Biology to Identify Molecular Targets for Vascular Disease Treatment (SysVasc) [HEALTH-2013 603288]

向作者/读者索取更多资源

CE-MS is applied in clinical proteomics for both the identification of biomarkers of disease and assessment of biomarkers in clinical diagnosis. The analysis is reproducible, fast, and requires only small sample volumes. However, successful CE-MS analysis depends on several critical steps that can be consolidated as follows: (i) proper sample preparation and fractionation, (ii) application of suitable capillary coating and appropriate CE-MS interfaces, to ensure the reproducibility and stability of the analysis, and (iii) an optimized clinical and statistical study design to increase the chances for obtaining clinically relevant results. In this review, we cover all these aspects, and present several examples of the application of CE-MS in clinical proteomics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据